Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Chemists Devise New Way to Prepare Molecules for Drug Testing

Published: Monday, August 19, 2013
Last Updated: Monday, August 19, 2013
Bookmark and Share
Metal-catalyzed cross-couplings of carbon bonds could enable creation of libraries of drug candidates to accelerate drug discovery.

James Bond had his reasons for ordering his martinis “shaken, not stirred.” Similarly, drug manufacturers need to make sure the molecules in a new drug are arranged in an exact manner, lest there be dire consequences. Specifically, they need to be wary of enantiomers, mirror-image molecules composed of the same atoms, but arranged differently.

“One mirror image could be therapeutic while another could be poisonous,” said Dr. Mark R. Biscoe, assistant professor of chemistry at The City College of New York. The classic case is thalidomide, a drug marketed in the 1950s and 1960s to treat morning sickness, which resulted in serious birth defects.

Professor Biscoe led a team of researchers at CCNY that developed a new method for preparing libraries of single-enantiomer molecules for therapeutic and toxicity studies that is faster and potentially less costly than methods now used in the pharmaceutical industry. Their findings were reported in Nature Chemistry.

Currently, drug developers typically rely on a chiral resolution process whereby compounds with roughly equal parts of the two enantiomers are separated into the individual enantiomers. Bioenzymatic processes can also be employed to generate single-enantiomer molecules. These strategies are wasteful and costly, Professor Biscoe explained.

He and colleagues found that a metal such as palladium could be employed to achieve a cross-coupling reaction with a single-enantiomer molecule without impacting the integrity of the mirror image formed in the product. By doing so, they could isolate one mirror image for evaluation as a drug candidate.

“By using a single-enantiomer partner in a cross-coupling reaction, we can rapidly generate a diverse library of biologically active molecules for use in drug screening,” he said.

The research was funded by the National Institutes of Health, City College, the Alfred P. Sloan Foundation and PSC-CUNY, with additional support from the National Science Foundation and the American Chemical Society Petroleum Research Fund.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!